The primary objective was to demonstrate non-inferiority in the percentage of subjects seroprotected for anti-diphtheria, anti-tetanus and anti-poliovirus 1, 2 and 3 and seropositive for anti-PT and anti-FHA when DPT-IPV vaccine was co-administered with HRV vaccine compared to staggered administration. This evidence concerns the gene F2 and diphtheria.